The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers

Emanuele Mazzola, Su Chun Cheng, Giovanni Parmigiani

Research output: Contribution to journalArticle

Abstract

Ductal carcinoma in situ (DCIS) is a precancerous lesion of the female breast and is strongly suspected to be a precursor of invasive breast cancer (IBC). Our goal is the estimation of the age-specific and lifetime penetrances of DCIS among carriers of either a BRCA1 or BRCA2 deleterious mutation. We jointly re-analyze the SEER9 database and a previous study by Claus et al. (JAMA 293:964-969, 2005). Estimation is performed via Bayes theorem after the evaluation of the ratio of age-specific DCIS incidences, and extrapolation to the general population of the study-specific penetrance obtained from Claus et al. From the SEER9 database, we estimate the lifetime risk of DCIS to be 0.98 %, in contrast to value of 12.5 % usually reported for IBC. By extending the result in Claus et al. to the general population, we obtain a lifetime risk for carriers of a deleterious mutation of either BRCA1 or BRCA2 of 6.21 % (95 % CI 6.09-6.33 %). The increase in lifetime risk of DCIS for a BRCA mutation carrier compared to a non-carrier is therefore about six-fold. Our quantification is directly relevant to the identification and genetic counseling of BRCA mutation carriers, and emphasizes the potential importance of including information on diagnoses of DCIS in counseling of individuals who are at familial risk for breast cancer. All these factors can contribute to a more specific and targeted prevention, potentially reducing the impact of IBC among BRCA mutation carriers.

Original languageEnglish (US)
Pages (from-to)315-318
Number of pages4
JournalBreast Cancer Research and Treatment
Volume137
Issue number1
DOIs
StatePublished - Jan 2013
Externally publishedYes

Fingerprint

Carcinoma, Intraductal, Noninfiltrating
Penetrance
Mutation
Breast Neoplasms
Databases
Bayes Theorem
Genetic Counseling
Population
Counseling
Breast
Incidence

Keywords

  • Age-specific risk
  • BRCA1
  • BRCA2
  • Ductal carcinoma in situ
  • Lifetime risk
  • Mutation carrier
  • Penetrance function

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers. / Mazzola, Emanuele; Cheng, Su Chun; Parmigiani, Giovanni.

In: Breast Cancer Research and Treatment, Vol. 137, No. 1, 01.2013, p. 315-318.

Research output: Contribution to journalArticle

Mazzola, Emanuele ; Cheng, Su Chun ; Parmigiani, Giovanni. / The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers. In: Breast Cancer Research and Treatment. 2013 ; Vol. 137, No. 1. pp. 315-318.
@article{5528bd0a1ac0444c9e5b4c4ccbf80f9c,
title = "The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers",
abstract = "Ductal carcinoma in situ (DCIS) is a precancerous lesion of the female breast and is strongly suspected to be a precursor of invasive breast cancer (IBC). Our goal is the estimation of the age-specific and lifetime penetrances of DCIS among carriers of either a BRCA1 or BRCA2 deleterious mutation. We jointly re-analyze the SEER9 database and a previous study by Claus et al. (JAMA 293:964-969, 2005). Estimation is performed via Bayes theorem after the evaluation of the ratio of age-specific DCIS incidences, and extrapolation to the general population of the study-specific penetrance obtained from Claus et al. From the SEER9 database, we estimate the lifetime risk of DCIS to be 0.98 {\%}, in contrast to value of 12.5 {\%} usually reported for IBC. By extending the result in Claus et al. to the general population, we obtain a lifetime risk for carriers of a deleterious mutation of either BRCA1 or BRCA2 of 6.21 {\%} (95 {\%} CI 6.09-6.33 {\%}). The increase in lifetime risk of DCIS for a BRCA mutation carrier compared to a non-carrier is therefore about six-fold. Our quantification is directly relevant to the identification and genetic counseling of BRCA mutation carriers, and emphasizes the potential importance of including information on diagnoses of DCIS in counseling of individuals who are at familial risk for breast cancer. All these factors can contribute to a more specific and targeted prevention, potentially reducing the impact of IBC among BRCA mutation carriers.",
keywords = "Age-specific risk, BRCA1, BRCA2, Ductal carcinoma in situ, Lifetime risk, Mutation carrier, Penetrance function",
author = "Emanuele Mazzola and Cheng, {Su Chun} and Giovanni Parmigiani",
year = "2013",
month = "1",
doi = "10.1007/s10549-012-2345-5",
language = "English (US)",
volume = "137",
pages = "315--318",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - The penetrance of ductal carcinoma in situ among BRCA1 and BRCA2 mutation carriers

AU - Mazzola, Emanuele

AU - Cheng, Su Chun

AU - Parmigiani, Giovanni

PY - 2013/1

Y1 - 2013/1

N2 - Ductal carcinoma in situ (DCIS) is a precancerous lesion of the female breast and is strongly suspected to be a precursor of invasive breast cancer (IBC). Our goal is the estimation of the age-specific and lifetime penetrances of DCIS among carriers of either a BRCA1 or BRCA2 deleterious mutation. We jointly re-analyze the SEER9 database and a previous study by Claus et al. (JAMA 293:964-969, 2005). Estimation is performed via Bayes theorem after the evaluation of the ratio of age-specific DCIS incidences, and extrapolation to the general population of the study-specific penetrance obtained from Claus et al. From the SEER9 database, we estimate the lifetime risk of DCIS to be 0.98 %, in contrast to value of 12.5 % usually reported for IBC. By extending the result in Claus et al. to the general population, we obtain a lifetime risk for carriers of a deleterious mutation of either BRCA1 or BRCA2 of 6.21 % (95 % CI 6.09-6.33 %). The increase in lifetime risk of DCIS for a BRCA mutation carrier compared to a non-carrier is therefore about six-fold. Our quantification is directly relevant to the identification and genetic counseling of BRCA mutation carriers, and emphasizes the potential importance of including information on diagnoses of DCIS in counseling of individuals who are at familial risk for breast cancer. All these factors can contribute to a more specific and targeted prevention, potentially reducing the impact of IBC among BRCA mutation carriers.

AB - Ductal carcinoma in situ (DCIS) is a precancerous lesion of the female breast and is strongly suspected to be a precursor of invasive breast cancer (IBC). Our goal is the estimation of the age-specific and lifetime penetrances of DCIS among carriers of either a BRCA1 or BRCA2 deleterious mutation. We jointly re-analyze the SEER9 database and a previous study by Claus et al. (JAMA 293:964-969, 2005). Estimation is performed via Bayes theorem after the evaluation of the ratio of age-specific DCIS incidences, and extrapolation to the general population of the study-specific penetrance obtained from Claus et al. From the SEER9 database, we estimate the lifetime risk of DCIS to be 0.98 %, in contrast to value of 12.5 % usually reported for IBC. By extending the result in Claus et al. to the general population, we obtain a lifetime risk for carriers of a deleterious mutation of either BRCA1 or BRCA2 of 6.21 % (95 % CI 6.09-6.33 %). The increase in lifetime risk of DCIS for a BRCA mutation carrier compared to a non-carrier is therefore about six-fold. Our quantification is directly relevant to the identification and genetic counseling of BRCA mutation carriers, and emphasizes the potential importance of including information on diagnoses of DCIS in counseling of individuals who are at familial risk for breast cancer. All these factors can contribute to a more specific and targeted prevention, potentially reducing the impact of IBC among BRCA mutation carriers.

KW - Age-specific risk

KW - BRCA1

KW - BRCA2

KW - Ductal carcinoma in situ

KW - Lifetime risk

KW - Mutation carrier

KW - Penetrance function

UR - http://www.scopus.com/inward/record.url?scp=84871733286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871733286&partnerID=8YFLogxK

U2 - 10.1007/s10549-012-2345-5

DO - 10.1007/s10549-012-2345-5

M3 - Article

C2 - 23184082

AN - SCOPUS:84871733286

VL - 137

SP - 315

EP - 318

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -